What Does Enbrel Cost in 2026 After Medicare Price Negotiation?

Enbrel (etanercept) is a biologic medication used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It works by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that drives inflammation. Before 2026, Enbrel had a list price of about $7,106 per 30-day supply, making it one of the highest-cost drugs in the country. Patients on Medicare Part D paid the full price until hitting their annual out-of-pocket cap.

The Inflation Reduction Act of 2022 (signed August 16, 2022) authorized the federal government to negotiate drug prices with manufacturers for the first time. Enbrel was one of the first 10 drugs selected. CMS announced a 67% price reduction on August 15, 2024, bringing the Medicare Maximum Fair Price to $2,355 per 30-day supply effective January 1, 2026. Medicare Part D enrollees benefit from this price automatically; they do not need to do anything to access it.

Despite FDA approvals of two biosimilar versions (Erelzi in 2016, Eticovo in 2019), neither is available in the US as of 2026. Amgen has defended extended patent protections through 2029, keeping biosimilar competition blocked. For patients who need cost relief today, the Amgen Safety Net Foundation provides free Enbrel for income-qualifying uninsured patients, and the Enbrel Co-Pay Program reduces costs for commercially insured patients. Those who may qualify for Medicaid can check Medicaid income limits for near-zero copays.

What Enbrel Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same enbrel can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospitals that administer Enbrel (which sometimes happens in infusion centers for new patients or those with compliance issues) bill at facility rates that include overhead, pharmacy preparation, nursing time, and supply chain markups. A drug that costs the hospital $2,000 to $3,000 can appear on an inpatient or outpatient facility bill at $5,000 to $9,000. Unlike retail pharmacies that apply manufacturer discounts, hospital pharmacies often bill at chargemaster rates that exceed any negotiated payer price.

Enbrel is primarily self-administered at home (subcutaneous injection), so most patients never encounter hospital billing for the drug itself. The highest cost scenarios involve initial administration training at an infusion or specialty clinic, or emergency administrations during a hospitalization for a separate condition. In those cases, patients can compare the billed amount to the Medicare Part D Maximum Fair Price of $2,355 per 30-day supply to gauge whether the charge is reasonable. Patients with low income who have not enrolled in Medicaid should check Medicaid income limits to see if near-zero copays are available.

The IRA's Medicare Drug Price Negotiation Program is specifically designed to reduce this cost gap. Before 2026, Medicare Part D enrollees paid a larger portion of the $7,106 list price before reaching their annual out-of-pocket cap. As of 2026, the negotiated $2,355 monthly price reduces the out-of-pocket trajectory and means most Medicare Part D beneficiaries on Enbrel hit the $2,100 annual OOP cap sooner in the year.

HCPCS J-Codes: What Appears on Your Bill

Enbrel may appear on clinical or hospital claims under HCPCS J-codes when administered by a healthcare professional. The primary code is J1438 for clinic-administered etanercept:

Patient Assistance Programs

Amgen, the manufacturer of Enbrel, operates two programs to reduce patient cost: the Amgen Safety Net Foundation for uninsured patients, and the Enbrel Co-Pay Program for commercially insured patients. Neither program covers Medicare or Medicaid beneficiaries directly:

Medicare Part D

Enbrel is covered under Medicare Part D (prescription drug plans), not Part B, because it is self-administered at home via subcutaneous injection. As of January 1, 2026, Enbrel's Medicare Part D Maximum Fair Price is $2,355 per 30-day supply, down from the pre-negotiation list price of $7,106. This is the price Medicare Part D plans must use as the upper limit when dispensing Enbrel to enrollees. The 2026 Part D annual out-of-pocket cap is $2,100, meaning most Enbrel patients on Medicare will reach the cap within the first few months of the year and pay $0 for the rest of the year.

Medicare Part D plans must include Enbrel on their formularies if it is selected for the IRA negotiation program. Enrollees do not need to take any action to access the negotiated price. If your Part D pharmacy charges more than $2,355 for a 30-day supply of Enbrel (50mg) in 2026, that is a billing error or formulary issue. Contact your Part D plan's member services immediately. You can also check Medicare eligibility at the Medicare eligibility page.

Common Enbrel Billing Errors

Enbrel billing errors are most common at specialty pharmacies and infusion centers. Check your bill for these issues before paying:

• Billed at the old pre-IRA list price ($7,106+) instead of the 2026 Medicare Maximum Fair Price ($2,355) for Part D patients
• Wrong J-code: clinic-administered doses billed under a non-etanercept TNF inhibitor code (e.g., adalimumab codes for Humira) instead of J1438
• Charged for home self-injection supply through Part B (facility rate) when it should be billed through Part D
• Biosimilar substitution error: charged for Enbrel brand pricing when a biosimilar was dispensed (note: US biosimilars are unavailable as of 2026, so any substitution would be erroneous)
• Duplicate billing: specialty pharmacy and hospital billing the same monthly supply separately

Frequently Asked Questions